$ABBV · AbbVie Inc.

AbbVie Inc. filed a current report on Form 8-K dated September 3, 2026, announcing that it had completed its acquisition of Apogee Therapeutics, Inc. The company issued a press release the same day to announce the closing of the transaction. The filing states that the press release is being furnished under Item 7.01, meaning it is not considered “filed” for purposes of securities law and is not automatically incorporated by reference into other AbbVie filings unless specifically stated.

The filing includes forward-looking statements about AbbVie’s 2026 financial guidance and the expected benefits of combining Apogee with AbbVie. It also discusses potential risks related to the acquisition, including the possibility that expected benefits may not be realized, challenges integrating Apogee’s business and employees, and uncertainties about the development and commercial potential of Apogee’s pipeline assets. The filing specifically names two acquired pipeline programs, zumilokibart and APG273, and notes that earlier clinical results may not predict later success. No financial terms or other specific transaction details are disclosed in the main body of the filing beyond the completion announcement itself.